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ABSTRACT 
In preventive drug treatment of cardiovascular disease, adverse drug effects often lead to 
suboptimal compliance with a risk of disability and shorter life expectancy. The overall aim 
of this thesis was to assess the nature and extent of adverse drug events (ADEs) from 
cardiovascular drugs in both women and men treated in routine care. A special focus was on 
bleeding events from antithrombotic treatment, in particular warfarin. Better understanding of 
potential differences in adverse drug effects between women and men could contribute to 
more successful prevention. Different sources of information were used in order to obtain 
information about sex differences in ADEs from cardiovascular drugs: spontaneous reporting 
of ADEs in routine care, a cross sectional study conducted at an Emergency Ward setting, 
data from national pharmacovigilance and prescription databases, medical files, and the 
national patient register. 
Study I describes the prevalence, preventability and reporting of adverse drug reactions 
(ADRs) in an emergency medicine ward. 40% of the patient population had at least one 
possible ADR, in 18% ADRs were the reason for or had contributed to admission, and 24% 
of these ADRs were preventable. The most common ADRs were cardiovascular and the 
under-reporting of ADRs was 99%. 
Study II presents sex differences in spontaneous reports on bleeding events from clopidogrel, 
low-dose aspirin and warfarin (1999-2010 and 2005-2010). We found that more men were 
dispensed clopidogrel although the reported bleeding event risk was higher in women. For 
low-dose aspirin, the reported bleeding event risk was lower in women while no sex 
difference was found for warfarin. 
Study III presents sex differences in spontaneous reports on ADEs from common 
antihypertensive drugs (2005-2012). In six out of ten groups of antihypertensives 
(angiotensin converting enzyme inhibitors (ACE-Is), ACE-I-combinations, angiotensin 
receptor blocker (ARB)-combinations, thiazides, diuretics and potassium sparing agents and 
dihydropyridine (DHP) calcium channel blockers), women had a higher prevalence of ADE-
reports with a potential linkage to dose exposure. Aldosterone antagonists was the only group 
with a higher prevalence of ADE-reports in men but without any sex difference in dose 
exposure. 
Study IV describes sex differences in severe bleeding events during warfarin treatment. 
Women had a lower incidence of bleeding which corresponded to a lower overall risk of 
severe bleeding in women, even after adjusting for age, comorbidity and co-medication. 
Women had a lower risk of CNS and urogenital bleeding. However, in the age groups 40-49 
and 50-59 as well as in patients with renal failure, women had a higher risk of severe 
bleeding than men. 
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1 INTRODUCTION 
Cardiovascular disease (CVD) is a major cause of premature death and disability worldwide 
[1]. In recent years, the mortality rates have decreased and most of the reduction in mortality 
rates from CVD is considered to be attributable to preventive treatment [2]. Good compliance 
to drug treatment is key for achieving successful prevention and if the patient experiences an 
adverse effect of the drug treatment there is a risk of suboptimal compliance. The threshold 
for tolerable adverse drug effects tends to be lower in preventive drug treatment with a higher 
risk of discontinuing the treatment [3]. It is not known if women or men experience more 
adverse events and are more likely to discontinue treatment. Better understanding of 
differences in adverse drug effects from cardiovascular treatment between women and men 
may provide important information for a successful prevention of cardiovascular disease. 
Sex difference is defined as the biological difference between women and men, as compared 
to gender difference being the psychosocial differences between women and men. In clinical 
cardiovascular pharmacology, both sex and gender differences play important roles with 
biological differences accounting for most of the pharmacokinetic and pharmacodynamic 
differences while gender is essential in the choice and administration of therapy and could 
therefore influence the potential adverse drug effects from cardiovascular treatment [4]. 
Potential differences in adverse drug effects between women and men could derive from 
differences in physiology, genetics, morbidity and therapeutic traditions, demographics and 
the propensity of reporting adverse drug events. In the literature, there are findings which 
indicate sex differences in physiological, pharmacodynamic or pharmacokinetic outcomes, 
but studies with findings which could be translated into clinically relevant differences in 
safety of drug treatment in general are sparse [5]. Accordingly, we need to gain a better 
knowledge and understanding of differences in adverse effects from drug treatment of CVDs 
among women and men.  
This thesis presents the prevalence, preventability, and reporting of adverse drug reactions 
(ADRs) in a tertiary care emergency medicine ward setting. Of special interest were sex 
differences in spontaneous reports from cardiovascular treatment, specifically adverse 
bleeding events from antithrombotic treatment and adverse drug events (ADEs) from 
common antihypertensive drugs. Furthermore, sex differences in bleeding events during 
warfarin treatment and the influence of comorbidities and co-medication on bleeding risk 
were explored. 
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2 AIMS 
The overall aim of this thesis is to identify possible sex differences in ADEs from 
cardiovascular medicines in routine care. 
 
- Describe the prevalence and preventability of ADRs and the frequency of formal 
reporting of ADRs according to current legislation in Emergency Medicine.  
 
- Study if sex differences are found in spontaneously reported adverse events for 
clopidogrel, low-dose aspirin, and warfarin treatment in routine care. 
 
- Explore if sex differences are found in spontaneously reported adverse events for 
antihypertensive drug treatment with betablockers, angiotensin converting enzyme 
(ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, and/or 
dihydropyridine calcium channel blockers (DHPs) in routine care. 
 
- Investigate if there are sex differences in the risk of bleeding during warfarin 
treatment in routine care and if such differences could be explained by different 
distribution of risk factors among women and men. 
 
 
  3 
3 BACKGROUND 
3.1 ADVERSE DRUG EFFECTS 
3.1.1 Definitions 
Adverse effects from pharmacological treatment constitute significant health and quality of 
life problems, especially in the elderly [6]. An adverse drug reaction (ADR) is defined as 
harm directly caused by the drug at normal doses and during normal use compared to an 
adverse drug event (ADE) with a wider definition, including ADRs, overdoses, dose 
reductions, and discontinuations of drug therapy [7]. However, many authors do not seem to 
follow these strict definitions for ADR and ADE. In this thesis, the term ADR was used in the 
emergency care ward setting study in which we had information on dosing through patient 
records. In the studies using register prescription data which lack information on dosing, the 
term ADE was more appropriate. 
 
3.1.2 Pharmacovigilance 
Drug-related risks are not always apparent until a drug is used in large numbers of patients, 
many of whom are older, more likely to be female, and have more comorbidities than the 
participants in the clinical trials. Randomized clinical trials often do not include adequate 
numbers of older patients to identify important safety issues in the general elderly patient 
population and this is especially the case for older women [8].  
The purpose of pharmacovigilance legislation is to collect safety information on drug use in 
normal health care settings for many patients who may differ from the study population. In 
EMA (European Medicines Agency) guidelines it is mandatory for health care professionals 
to report all suspected ADEs to the national competent authority. This feedback loop leads to 
improved safety information and may lead to increased pharmacovigilance regarding certain 
side effects (Black box warning, black triangle) or contribute to withdrawal of market 
authorization [9].  
3.1.2.1 Reporting 
Since 2012 spontaneous adverse drug event reports are registered in Sweden in the national 
pharmacovigilance database (BiSi, “Biverkningar och Signaler”), managed by the Swedish 
Medical Products Agency (MPA) [10].  
The previous MPA register was called SWEDIS (Swedish drug information system) before 
the change of legislation in 2012 [11]. In SWEDIS, physicians, dentists, and nurses were 
supposed to report serious ADEs; ADEs not mentioned in the Summary of Product 
Characteristics (SPC), ADEs related to the use of new drugs (≤2 years after authorization) 
except those already labeled as common in the SPC; and ADEs that seem to be increasing in 
incidence, to regional pharmacovigilance centers [11]. 
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3.1.2.2 Causality assessment 
The reported, suspected ADRs sent to the Swedish MPA are assessed using the WHO-UMC 
system, the World Health Organization Collaborating Centre for International Drug 
Monitoring (Uppsala Monitoring Centre, Sweden) for standardized case causality 
assessments [12]. This assessment for case reports is the most widely used and accepted 
causality assessment scale in clinical practice (Table 1) alongside the Naranjo ADR 
Probability Scale [13]. 
 
Table 1. WHO-UMC causality categories [12] 
Causality term Assessment criteria 
Certain 
 Event or laboratory test abnormality with plausible time relationship to drug intake  
 Cannot be explained by disease or other drugs 
 Response to withdrawal plausible (pharmacologically, pathologically)  
 Event definitive pharmacologically or phenomenologically (i.e. an objective and 
specific medical disorder or a recognised pharmacological phenomenon)  
 Rechallenge satisfactory if necessary 
Probable/ 
Likely 
 Event or laboratory test abnormality with reasonable time relationship to drug 
intake  
 Unlikely to be attributed to disease or other drugs 
 Response to withdrawal clinically reasonable 
 Rechallenge not required 
Possible 
 Event or laboratory test abnormality with reasonable time relationship to drug 
intake  
 Could also be explained by disease or other drugs 
 Information on drug withdrawal may be lacking or unclear 
Unlikely 
 Event or laboratory test abnormality with a time to drug intake that makes a 
relationship improbable (but not impossible)  
 Disease or other drugs provide plausible explanations 
Conditional/ 
Unclassified 
 Event or laboratory test abnormality 
 More data for proper assessment needed, or 
 Additional data under examination 
Non-assessable/ 
Unclassifiable 
 Report suggesting an adverse reaction 
 Cannot be judged because information is insufficient or contradictory  
 Data cannot be supplemented or verified 
 
The reports of the suspected ADRs sent to the Swedish MPA are also assessed as being 
serious or not. An ADR was assessed as serious if it fulfilled the World Health Organization 
(WHO) criteria for a serious adverse drug reaction, that is, if it was lethal, life-threatening, 
permanently disabling, lead to hospital admission, prolongation of hospital stay, or classified 
as an “important medical event” [14, 15]. 
Another causality assessment scale, the Naranjo ADR probability score was used when 
assessing the causality of the ADRs in the Emergency ward study. This scale assigns the 
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ADR to a probability category; definite, probable, possible, or doubtful. Ten questions are to 
be answered with a “yes”, “no” or “do not know” being worth a certain point and the total 
score puts the ADR in a probability category; definite ≥9, probable 5 to 8, possible 1 to 4, 
doubtful ≤0 (Table 2) [13]. 
 
Table 2. Naranjo ADR probability score [13] 
 Yes No  Do not know Score 
1. Are there previous conclusive reports on this reaction? +1 0 0  
2. Did the adverse event appear after the suspected drug was 
administered? 
+2 -1 0  
3. Did the adverse reaction improve when the drug was 
discontinued and a specific antagonist was administered? 
+1 0 0  
4. Did the adverse reaction reappear when the drug was 
readministered? 
+2 -1 0  
5. Are there alternative causes (other than the drug) that could 
on their own have caused the reaction? 
-1 +2 0  
6. Did the reaction reappear when a placebo was given? -1 +1 0  
7. Was the drug detected in the blood (or other fluids) in 
concentrations known to be toxic? 
+1 0 0  
8. Was the reaction more severe when the dose was increased 
or less severe when the dose was decreased? 
+1 0 0  
9. Did the patient have a similar reaction to the same or similar 
drugs in any previous exposure? 
+1 0 0  
10. Was the adverse event confirmed by any objective 
evidence? 
+1 0 0  
   Total score  
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3.1.2.3 Preventability assessment 
In the emergency ward study, the preventability of ADRs was assessed using the Hallas’ 
avoidability criteria [16]. These include four categories, “definitely avoidable”, “possibly 
avoidable”, “not avoidable”, and “unevaluable”. Definitely avoidable; the drug event was 
clearly unrealistic or due to a drug treatment procedure inconsistent with present day 
knowledge of good medical practice, taking the known circumstances into account. Possibly 
avoidable; the drug event could have been avoided by an effort exceeding the obligatory 
demands. Not avoidable; the drug event could not have been avoided by any reasonable 
means, or it was an unpredictable event of a treatment fully in accordance with good medical 
practice. Unevaluable; the data for rating could not be obtained or the evidence was 
conflicting. 
 
3.2 SEX AND GENDER DIFFERENCES IN ADVERSE DRUG EVENTS FROM 
CARDIOVASCULAR MEDICINES 
In recent years, the importance of sex (determined by genetics) and gender (related to social 
factors) in the response to drug treatment has been recognized with increasing amount of data 
showing sex differences in physiology, pharmacokinetics, and pharmacodynamics [17]. 
These sex and gender differences may be due to therapeutic traditions, the propensity of 
ADE-reporting, morbidity, and demographic differences. Thus, there is a need for more 
information on how these differences translate into clinically relevant sex differences in 
ADEs [5]. 
 
3.2.1 Physiological differences 
3.2.1.1 Bioavailability, distribution and elimination of drugs  
There are numerous factors affecting the bioavailability and distribution of drugs such as the 
ratio of lean to fat tissue, circulating plasma volume, and the amount of plasma proteins 
binding the drug [18]. Since women have lower body mass and higher lipid levels [19, 20], 
lipid soluble drugs may have a greater volume of distribution in women [21].  
Furthermore, the circulating plasma volume is generally reduced in women with variations 
throughout the menstrual cycle [18], and with sex hormones affecting gastrointestinal 
motility leading to a slower transit time reported in women [22, 23]. Sex hormones also affect 
plasma levels and excretion of drugs with narrow therapeutic indexes, such as warfarin and 
digoxin, leading to significant clinical effects [24]. Additionally, the glomerular filtration rate 
(GFR) is directly proportional to weight and therefore generally higher in men. For digoxin, 
there are reports of increased mortality in women where reduced GFR has led to higher drug 
serum concentrations in the upper normal range due to reduced distribution volume and lower 
drug elimination [18].  
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3.2.1.2 Cardiovascular medicines and physiological differences 
There are reports indicating differences between women and men in response to 
cardiovascular treatment [25]. Since sex hormones affect the renin angiotensin aldosterone 
system (RAAS) different response to ACE-Is and ARBs may be anticipated [26]. Estrogens 
increase the availability of angiotensinogen and plasma levels of angiotensin II, but decrease 
renin and angiotensin converting enzyme (ACE) activities and the expression of angiotensin 
receptor I. In contrast, androgens up-regulate the RAAS system. If these hormonal influences 
impact efficacy and safety of drug treatment involving the RAAS is not clear [27]. 
Furthermore, there are sex differences in the response to the DHP amlodipine with a larger 
blood pressure (BP) reduction and a higher incidence of edema in women, despite dose 
adjustments for body weight, and with an adjustment for the use of hormone replacement 
therapy (HRT) [28]. A better response to antithrombotic treatment with aspirin 
(acetylsalicylic acid) in women may be due to higher bioavailability, slower clearance and a 
longer half-life of aspirin [25]. Aspirin seems to inhibit spontaneous platelet aggregation in 
men only [24], a finding that may explain aspirin resistance, which is more frequently found 
in women. Additionally, the aspirin-induced inhibition on platelet aggregation has been found 
to be induced by testosterone, while estradiol was found to have no impact on aspirin-induced 
inhibition [17]. For clopidogrel, no differences have been found in plasma levels of the main 
metabolite between women and men [25] and there are no other findings in the literature 
pointing to sex differences in the physiological responses to clopidogrel treatment.  
 
3.2.2 Genetic differences 
3.2.2.1 Drug metabolizing cytochrome P450 enzymes 
Sex differences have been found for some of the drug metabolizing cytochrome P450 
enzymes [24]. The higher expression of CYP2D6 in men leads to an increased drug clearance 
compared to women [29]. Women have a higher incidence of ADE and higher plasma 
concentration of beta blockers, metabolized by CYP2D6 [30]. Women have a higher 
expression of CYP3A4 and an increased clearance of several CYP3A drug substrates [24]. It 
has been hard to present data supporting the clinical relevance of these sex differences [29].  
3.2.2.2 ACE gene and bradykinin receptor 
ACE gene polymorphism has been demonstrated and genetic variants with high expression of 
ACE have been linked to increased plasma levels of ACE and a major risk for cardiovascular 
disease. In addition, the renoprotective effect of ACE-Is has been reported to be greater in 
women with the D/D genotype of the ACE-1 enzyme compared to men with the same 
genotype [26]. Cough and angioedema are more frequent in women compared to men during 
ACE-I treatment. ACE-I related cough seems to be associated with polymorphism of the 
bradykinin B2 receptor with some evidence pointing to the effect of the polymorphism being 
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sex-specific [31]. Most women discontinue treatment with ACE-Is because of cough while 
most men stop treatment due to hypotension [26]. 
 
3.2.3 Differences in morbidity, demography and therapeutic traditions 
3.2.3.1 CVD risk and sex and gender differences  
There are several notable differences between women and men in CVD incidence, mortality, 
risk-factor profiles, outcomes and clinical presentation. In all age groups, except the oldest, 
CVD prevalence, incidence and mortality rates tend to be higher in men compared to women. 
Women experience their first cardiovascular events, e.g. myocardial infarction (MI) and 
stroke later in life than men. The protective effect of estrogen on the development of CVD 
risk factors, such as hypertension and dyslipidemia, is the most cited reason for these sex and 
gender differences. However, HRT in postmenopausal women does not reduce the CVD risk 
and is not recommended for primary or secondary prevention of CVD. Additionally, oral 
contraceptives are associated with an increased risk of hypertension. During pregnancy and 
the postpartum period women have an increased risk of stroke. Women also experience 
poorer outcomes when they have a CVD event (post MI or stroke), partly due to delayed 
treatment start. Another cited reason is that women tend to be older with more comorbidity 
than men at the time of the CVD event [32]. These sex and gender differences in CVD risk 
should be taken into consideration when exploring sex differences in ADEs from 
cardiovascular medicines. 
3.2.3.2 ADE-related hospital admissions and sex and gender differences 
The rate of ADEs is higher in women, both in hospital and community settings [33]. 
However, data on sex and gender differences in ADE-related hospital admissions are found 
with female gender has been identified as an independent risk factor for ADE-related hospital 
admissions in the general population by some authors [34-39] but not by others [40-46]. 
Among older Swedish patients receiving home healthcare, very old women with impaired 
renal function were associated to the ADR-related hospital admissions to a high extent [47]. 
In older Italian patients from geriatric and internal medicine wards, female sex, as well as the 
number of concomitant drugs and alcohol were associated with ADR-related hospitalizations. 
Furthermore, older age and frailty were found to be predictors for severe ADRs and with 
cardiovascular medicines causing approximately 45 percent of the ADR-related 
hospitalizations [48]. 
3.2.3.3  ADEs, cardiovascular medicines and sex and gender differences 
Women have a higher incidence of ADEs from cardiovascular medicine with drug-induced 
arrhythmias, e.g. supraventricular tachycardia (SVT) and QT syndrome [49], with an 
increased incidence of developing severe arrhythmia, Torsades de Pointes (TdP), from QT-
prolonging drug therapy [50]. Sotalol was the most frequently suspected drug in the reports of 
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drug-induced TdPs in a review of the Swedish pharmacovigilance database with female 
gender being one of the risk factors [51].  
Furthermore, there are reports on ADEs from ACE-Is with drug-induced cough being 
significantly more reported in women compared to men [52] and beneficial effects from 
ACE-Is being more frequent in men while women experienced more side effects from ACE-
Is [53]. The most prominent ADE of aldosterone antagonist is gynecomastia, which only 
affects men and when given to patients as an add-on treatment in heart failure, excessive 
hypotension is more prevalent in women [54]. In the case of ADEs from antithrombotic 
medicines such as warfarin, there are conflicting data in whether there is a sex difference. 
Most interventional and some observational studies did not find any difference in bleeding 
risk between women and men during warfarin treatment [55-61]. However, an increased risk 
for severe bleeding in male patients was reported in a Swedish observational study on 
patients with several different indications for warfarin [62]. An observational study from 
Canada on AF patients presented an increased risk of major bleeding in women on warfarin 
[63]. There is also conflicting data on sex differences in the bleeding risk from low-dose 
aspirin with some studies finding no sex difference in the bleeding risk [64, 65], while in 
another study on aspirin-treated patients, a higher risk of major bleeding was found in men 
compared to women [66]. 
3.2.3.4 Therapeutic traditions and gender differences 
Differences between women and men in therapeutic traditions have been found in the 
literature. According to a Swedish population-based drug utilization study anticoagulants 
were dispensed to a larger extent to men compared to women, indicating underuse of 
anticoagulants in women with atrial fibrillation (AF) [67]. In 2011 (at time of the introduction 
of the non-vitamin K oral anticoagulants, NOACs) the use of oral anticoagulants (mostly 
warfarin) was less frequent in women and more women were treated with aspirin only 
compared to men. Similar use patterns were presented in Canadian patients with new-onset 
AF, i.e. older women were twice as likely to receive low-dose aspirin and half as likely to 
receive warfarin compared to men in the same age group [63]. In 2015 the previous sex 
difference regarding use of oral anticoagulants (warfarin and NOAC) disappeared. However, 
when comparing warfarin treated patients of the same stroke risk, more men than women 
were treated with warfarin [68].  
Differences between women and men in therapeutic traditions are also found for the RAAS-
agents with ACE-Is being dispensed to a higher degree in men, probably due to a higher 
frequency of drug-induced cough in women. The ARBs, on the other hand, have been found 
to be dispensed to the same extent in both sexes, with a suggested underuse of RAAS-agents 
in women [67]. Furthermore, there are other findings on gender disparities in 
antihypertensive treatment, with men receiving more ACE-Is and women more frequently 
treated with diuretics [69, 70] and at the same time less likely to be treated with beta blockers, 
calcium antagonists, compared to men [71, 72].  
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3.2.4 Reporting differences 
There are studies showing that women seek healthcare more often than men [73, 74] which 
could lead to a higher reporting rate of adverse drug events in women. There are few studies 
on sex and/or gender differences in ADEs reported to pharmacovigilance centers. In an 
ambulatory medical population, women generally reported more symptoms compared to men 
[75, 76]. Differences between women and men in the onset and description of symptoms 
influenced the reporting of ADEs [77]. In a German pharmacovigilance database study, 
women more frequently experienced ADEs associated with diuretics compared to men, 
which could not be explained by women being prescribed more diuretics [78]. Results from a 
Swedish pharmacovigilance database study indicate that healthcare professionals more 
frequently reported ADEs for the oldest patients and for women [79].  
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4 METHODS 
4.1 STUDY DESIGNS 
In paper I, the electronic patient records of patients admitted to an emergency ward were 
reviewed in this prospective cross sectional study. In paper II and III, we analyzed ADE-
reports and dispensed prescriptions in women and men respectively (cross sectional 
analyses). In paper IV, women and men with warfarin treatment fulfilling the eligibility 
criteria were included in this cohort study. 
 
4.2 DATA SOURCES 
4.2.1 National pharmacovigilance database 
4.2.1.1 The Swedish Drug Information System 
Spontaneous ADE reports are registered in the national pharmacovigilance database managed 
by the Swedish MPA. Before 2012, this database was called SWEDIS, established in 1965 
and contained ADEs reported with the former legislation [11]. SWEDIS contains data from 
1965 until October 2013, with more than 130 000 reports at the end of 2012. The severity 
criteria were introduced in SWEDIS 1998 and from 2006 reports on ADEs were also 
registered as serious if they were assessed as “important medical events”. In 2008, consumer 
reporting started in Sweden with the reports being collected in a separate database and 
therefore not included in the studies with ADE-report data from SWEDIS (paper II and III). 
 
4.2.2 National health registers 
4.2.2.1 The Prescribed Drug Register 
The Prescribed Drug register (PDR) was established in 1999 and is held by the National 
Board of Health and Welfare (NBHW) [80] and since July 2005 patient identity data on all 
dispensed drugs is available. The register has a coverage of >99 % with unique identifiers of 
all drugs dispensed to the entire Swedish population [81]. All medications in the PDR are 
classified by the Anatomical Therapeutic Chemical classification (ATC) codes [82]. The 
dispensed prescription data in the PDR holds details on the sex and age of the patient, the 
profession, and workplace of the prescriber and includes medications prescribed in primary 
and specialized care. Over-the-counter (OTC) medications and medications used in hospitals 
for inpatient care are not included [81]. The PDR has a high validity where >99.7% of all 
prescriptions have a personal identity number (PIN) recorded [83]. Dispensed prescription 
data from the PDR was used in paper II, III, and IV. 
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4.2.2.2 The National Patient Register 
The National Patient Register (NPR) contains nationwide data on primary and secondary 
diagnoses and surgical procedures recorded at Swedish hospitals. Since 1987, inpatient care 
data is provided and data on outpatient encounters from both public and private caregivers is 
provided since 2001. Diagnoses are recorded by the international classification of diseases 
(ICD) system [84], with the 10th version (ICD-10) available since 1997 [85-89]. The register 
also holds information on hospital surgical procedures using the Nordic classification of 
surgical procedures [90]. Data from the NPR was used in paper IV. 
4.2.2.3 The Cause of Death Register 
The Cause of Death Register is held by the NBHW and contains information, since 1961 and 
onwards, on dates and primary and contributing causes of death for all deceased residents in 
Sweden [91]. The date of death was retrieved from this register in paper IV. 
4.2.2.4 The National Population Register 
The National Population Register includes information on date of birth, sex, death, and burial 
site, migration, residency and civil status of all Swedish residents since 1961 [92]. A central 
database at the Swedish Tax Agency distributes the information in the register to central and 
regional authorities who use the data [93]. Data from this register was used in paper IV. 
4.2.2.5 The National Cancer Register 
For both the physician detecting the cancer and the verifying pathology departments it is 
mandatory to register the diagnosis in the National Cancer Register (established in 1958). The 
register has high coverage [94, 95] and it contains data on cancer diagnosis using the ICD 
classification [84]. Data from this register was used in paper IV. 
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4.3 PAPER I 
4.3.1 Study design and analyses 
706 patients admitted to one of the emergency wards (AVA 1) at Karolinska University 
Hospital Solna, Stockholm were periodically included during the study period (September 
2008 -September 2009). The electronic patient records were reviewed for severity, causality, 
and the preventability of ADRs, as well as the contribution to hospital admission. The ADRs 
were classified using the Naranjo ADR probability score [13]. The ADRs that were assessed 
as having caused and contributed to admission were additionally assessed for preventability 
by using the Hallas’ avoidability criteria [16]. The formal reporting of the ADRs to the 
national authority, according to current legislation, was noted. Additionally, by using the 
CKD-EPI formula [96], the impact of decreased GFR was assessed. The influence of age, the 
number of concomitant drugs, and sex in relation to the probability of presenting with an 
ADR were investigated. The association between age, sex, and ADRs was calculated 
separately for women and men in different age groups. For these calculations, descriptive 
statistics were used with p<0.05 considered statistically significant. 
 
4.4 PAPER II 
4.4.1 Study design and analyses 
For clopidogrel, low-dose aspirin, and warfarin, differences between women and men 
concerning bleeding event reports were analyzed separately. As the primary analysis, the total 
number of bleeding event reports from SWEDIS were adjusted for dispensed prescriptions in 
the PDR. The drug exposure was analyzed during two different time frames, 1999-2010 and 
2005-2010, in women and men respectively. The total number of dispensed prescriptions and 
defined daily doses (DDDs) of each substance were obtained for the period 1999-2010. The 
number of individuals with at least one dispensed prescription (individuals exposed) and the 
total number of dispensed prescriptions and DDDs were obtained from 2005-2010. As a 
secondary analysis, the total number of serious reports adjusted for prescription data were 
calculated. For low-dose aspirin, the mean doses in women and men respectively were 
assessed by analyzing the distribution between different dispensed tablet strengths, i.e., 75 
mg or 160 mg. Other antithrombotic treatment chosen as co-medication in the bleeding 
reports and dispensed co-prescriptions were also analyzed. The descriptive statistics data 
were presented as proportions and risk ratios (RRs) with 95% confidence intervals (CI). 
 
4.5 PAPER III 
4.5.1 Study design and analyses 
For ACE-Is and ARBs, with or without thiazide, diuretics (thiazide, potassium sparing 
agents, sulfonamides, aldosterone antagonists), selective beta blockers, and DHPs, the total 
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number of ADE-reports in SWEDIS was adjusted to exposed individuals and dispensed 
DDDs in the PDR among women and men respectively (2005-2012). The total amount of 
serious reports for the ten different groups of antihypertensives were also adjusted to 
prescription data as a secondary analysis. Additionally, the most frequently reported type of 
ADEs were collected. For the selected group of antihypertensives, the most frequently 
reported antihypertensive co-medications (classified as suspected in the report) and the most 
frequently dispensed co-prescribed antihypertensives were collected. To estimate dose 
exposure, both DDDs per individuals exposed and DDDs per dispensed prescription per year 
were calculated in women and men respectively divided by age group (0-49 years, 50-74 
years, ≥75 years). Descriptive statistics were used with 95% CIs when presenting proportions 
and sex differences as odds ratios (ORs). 
 
4.6 PAPER IV 
4.6.1 Study design and analyses 
During the study period (2007 -2011), women and men (≥18 years) with a dispensed 
prescription of warfarin were included in the study cohort. The first date of warfarin 
dispensing during this period was the index date and only patients with no VKA (vitamin K 
antagonist) use 1 year prior to index date (new users) were included. Subjects not resident in 
Sweden the year before and including index date were excluded. The cohort patients were all 
followed for the occurrence of bleeding events until 12 months (maximum) after the index 
date, death, or emigration, whichever occurred first, see flow chart (Fig 1).  
The indications for warfarin included in the analyses were identified through the main and 
secondary discharge diagnosis, as well as the outpatient visit diagnosis in the NPR 
(Supplementary Table 1). For comorbidities, hospital admissions, and outpatient contacts 
were identified up to 10 years before index date and a modified HAS-BLED score [97, 98] 
was used for classifying the risk of bleeding (Tables 1 and 2). Additionally, co-medication 
and clinically relevant interacting drugs were considered and adjusted for in the analysis 
(Tables 1 and 2).  
Descriptive statistics are presented as numbers and proportions. Hazard ratios (HR) for severe 
bleeding comparing women to men, and the association of bleeding with indications, 
comorbidities/risk factors, and co-medication were estimated using multiple Cox regression 
adjusted for age (except for age-stratified analyses) and presented with a 95% CI. Effect 
modification for each covariate by sex was investigated. In additional regression models, age 
as a continuous variable was used for adjustments and co-medications that could lead to drug 
interactions with warfarin were included. 
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4.7 ETHICAL CONSIDERATIONS 
Ethical considerations in research are primarily focused on the safety and autonomy of the 
individual, the individual’s perspective. In Sweden, with publicly funded health care, there is 
also a group perspective to be considered where the resources should be spent in a utilitarian 
manner with maximal “benefit” for society. The goal in publicly funded health care is also to 
be equal and needs-based. All included studies were approved by the Regional Ethical 
Review Board in Stockholm.  
In Paper I, the patient treatment was according to clinical routine and this was not an 
interventional study. This was an observational study that was performed with informed 
consent for most patients. Patients unable to give informed consent were also included after 
permission from the Regional Ethical Review Board in Stockholm since the benefit of 
complete data collection, especially for this high-risk group, was assessed as superior to the 
invasion of privacy (Dnr 2008/982-31/3 and 2009/2130-32). 
Paper II and III are both register studies with data extracted from the former Swedish 
pharmacovigilance database SWEDIS and the PDR with no risk for the participants to be 
identified. The ADE-reports are analyzed on a group level and specific individual reports are 
not described or detailed in publications. No risk or benefit for the individual in this case but 
benefits for patients in general and society with gained knowledge of possible sex differences 
in ADE reporting (Dnr 2010/788-31/5 and 2012/1581-32). 
In Paper IV, with data from the NPR, the PDR, and the National Population Register, there 
could be a potential risk for the individual to be identified with the analyses of specific 
diagnoses and dispensed drugs. In this case, all data analyzed are anonymous and grouped so 
that no individual can be identified. There are benefits for the patients, health care, and 
society with more knowledge of possible sex differences in bleeding complications from 
warfarin treatment (Dnr 2013/1850-31/1 and 2014/2215-32). 
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5 RESULTS 
5.1 PAPER I 
Women (n=351) and men (n=355) were evenly represented in the total patient population 
(n=706) and the median age was slightly higher in women (Table 1). The patients with ADRs 
(n=284) were older, had a higher percentage of women (54% vs 46%), a higher number of 
drugs, lower GFRs, and longer duration of hospital stay compared to the non-ADR-
population. 
 
Table 1. Patient characteristics. Modified from Paper I [99]  
 All patients 
(n=706) 
Women 
(n=351) 
Men 
(n=355) 
ADR-patients 
(n=284) 
Non-ADR-
patients 
(n=422) 
Age (years1) 
 
71 
(58-82) 
72 
(59-84) 
69 
(57-81) 
75 
(63-84) 
68 
(53-81) 
Number of drugs1 
 
6 
(2-11) 
7 
(3-12) 
6 
(2-10) 
8 
(4-13) 
5 
(2-10) 
Duration of hospital stay (days1) 2 
(2-4) 
2 
(2-4) 
2 
(2-3) 
3 
(2-4) 
2 
(2-3) 
GFR (mL/min1,2) 
 
72 
(46-93) 
72 
(44-97) 
71 
(48-91) 
65 
(37-87) 
75 
(52-98) 
1median (inter quartile range), 2 CKD-EPI formula 
 
Approximately 40 % of the entire patient population had at least one possible ADR (n=284). 
Preventability assessment was restricted to the ADRs causing or contributing to admission 
(n=129) and 24% (31/129) were considered avoidable.  
ADR-admissions seemed to be more common in older women above 75 years compared to 
the same age group of men (Fig 1). In the multivariable regression model, sex was not 
significantly associated with the risk for ADRs (p=0.27), while age and number of 
concomitant drugs were (p<0.01 and p<0.001).  
Cardiovascular ADRs were both the most frequent ADRs and the most frequent preventable 
ADRs, followed by electrolyte disturbances and hemorrhage. Antihypertensives were 
responsible for the cardiovascular ADRs while hemorrhages were assessed as the most 
frequent serious ADRs and mainly caused by low-dose aspirin.  
During the study, only two reports were sent to the MPA although 146 patients had at least 
one ADR which should have been reported to the MPA according to current legislation. 
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Fig 1. The distribution, in different age groups, of ADRs causing or contributing to admission, in women and 
men. Modified from Paper I [99] 
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5.2 PAPER II 
For clopidogrel (standard dose of 75 mg once daily, OD), the number of dispensed 
prescriptions was higher in men but the risk of reported bleeding events was significantly 
higher in women when adjusting for the number of exposed individuals (RR 1.40; 95%CI 
1.00-1.96, Table 1).  
For low-dose aspirin (75-320 mg OD), the risk of reported bleeding events was significantly 
lower in women, both when adjusting for exposed individuals (RR 0.80; 95% CI 0.66-0.97, 
Table 2) and the number of dispensed prescriptions during both time periods (Table 2). In 
men, the proportions of patients dispensed 160 mg once or twice daily was higher compared 
to women with a ratio of 1.2. 
For warfarin (individualized dosing), no difference in bleeding event reports was found 
between women and men when adjusting for the number of exposed patients (RR 1.01; 95% 
CI 0.87-1.17, Table 3). However, when adjusting for the number of dispensed prescriptions 
women had a higher risk of reported bleeding events (Table 3).  
Overall, the RRs for serious bleeding events were in line with the total bleeding reports. For 
all three substances, the proportion of reports on CNS and GI bleedings were higher in men. 
Additionally, bleeding reports constituted 89, 74 and 57 percent of the total reports for low-
dose aspirin, warfarin, and clopidogrel respectively during 1999-2010. 
 
Table 1. Reports and exposure data for clopidogrel. Modified from Paper II [100] 
 Number of 
prescription 
(Rx) 
Individuals 
exposed 
Total 
reports 
with 
bleeding 
events1 
RR 
adjusted 
for nr of 
Rx2 (CI3) 
RR 
adjusted 
for 
individuals 
exposed2 
(CI3) 
Serious 
reports 
with 
bleeding 
events 
RR 
adjusted 
for nr of 
Rx2 (CI3) 
RR 
adjusted 
for 
individuals 
exposed2 
(CI3) 
1999-2010 
 
        
Total 
 
1 794 605 NA 219   194   
Women 824 138 
 
NA 93   78   
Men 970 467 
 
NA 126   116   
RR2  
 
  0.87 
(0.66-1.14) 
NA  0.79 
(0.59-1.06) 
NA 
2005-2010 
 
        
Total 1 117 465 
 
157 179 139   120   
Women 516 199 
 
59 495 64   53   
Men 601 266 
 
97 684 75   67   
RR2  
 
  0.99 
(0.71-1.39) 
1.40 
(1.00-1.96) 
 0.92 
(0.64-1.32) 
1.30 
(0.91-1.86) 
1 For details on reported events, see Table 4., 2 RR women vs men, 3 0.95 Confidence Interval  
 
 20 
Table 2. Reports and exposure data for low-dose aspirin. Modified from Paper II [100] 
 Number of 
prescription 
(Rx) 
Individuals 
exposed 
Total 
reports 
with 
bleeding 
events1 
RR 
adjusted 
for nr of 
Rx2 (CI3) 
RR 
adjusted 
for 
individuals 
exposed2 
(CI3) 
Serious 
reports 
with 
bleeding 
events 
RR 
adjusted 
for nr of 
Rx2 (CI3) 
RR 
adjusted 
for 
individuals 
exposed2 
(CI3) 
1999-2010 
 
        
Total 
 
39 179 062 NA 676   625   
Women 21 100 226 
 
NA 293   270   
Men 18 079 512 
 
NA 383   355   
RR2  
 
  0.66 
(0.56-0.76) 
NA  0.65 
(0.56-0.76) 
NA 
2005-2010 
 
        
Total 21 973 285 
 
1 082 352 417   372   
Women 11 987 930 
 
521 201 178   156   
Men 9 985 355 
 
561 151 239   216   
RR2  
 
  0.62 
(0.51-0.75) 
0.80 
(0.66-0.97) 
 0.60 
(0.49-0.74) 
0.78 
(0.63-0.96) 
1 For details on reported events, see Table 5., 2 RR women vs men, 3 0.95 Confidence Interval  
 
Table 3. Reports and exposure data for warfarin. Modified from Paper II [100] 
 Number of 
prescription 
(Rx) 
Individuals 
exposed 
Total 
reports 
with 
bleeding 
events1 
RR 
adjusted 
for nr of 
Rx2 (CI3) 
RR 
adjusted 
for 
individuals 
exposed2 
(CI3) 
Serious 
reports 
with 
bleeding 
events 
RR 
adjusted 
for nr of 
Rx2 (CI3) 
RR 
adjusted 
for 
individuals 
exposed2 
(CI3) 
1999-2010 
 
        
Total 
 
5 113 359 NA 1386   1334   
Women 2 053 435 
 
NA 618   598   
Men 3 059 924 
 
NA 768   736   
RR2  
 
  1.20 
(1.08-1.33) 
NA  1.21 
(1.09-1.35) 
NA 
2005-2010 
 
        
Total 2 941 179 
 
271 003 717   677   
Women 1 171 801 
 
113 627 302   290   
Men 1 769 378 
 
157 376 415   387   
RR2  
 
  1.10 
(0.95-1.27) 
1.01 
(0.87-1.17) 
 1.13 
(0.97-1.32) 
1.04 
(0.89-1.21) 
1 For details on reported events, see Table 6., 2 RR women vs men, 3 0.95 Confidence Interval  
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5.3 PAPER III 
Women had a higher prevalence of ADE-reports in six of the ten subgroups of 
antihypertensives; ACE-Is (OR 1.21; 95% CI 1.09-1.35), ACE-I with thiazide combinations 
(OR 1.61; 1.44-1,79), ARB with thiazide combinations (2.12; 1.47-3.06), thiazides 
(1.78;1.33-2.39), diuretics with potassium sparing agents (1.62; 1.22-2.17), and DHPs (1.40; 
1.17-1.67). For these groups, we also found a potential linkage to a sex difference in dose 
exposure.  
In men, a higher prevalence of ADE-reports was observed for aldosterone antagonists (0.75; 
0.59-0.97, Table 8) but no difference in dose exposure between women and men was found. 
Overall, the ORs for the reports of serious ADEs were higher than expected for thiazides and 
diuretics with potassium sparing agents (Table 5 and 6). 
 
Table 5. Reports and exposure data for thiazides (ATC code C03AA) 2005-2012. Modified from Paper III [101] 
 Individuals 
exposed 
Number of 
million 
DDDs 
Total 
reports 
OR 
adjusted 
for individ. 
exposed1 
(CI2) 
OR 
adjusted 
for nr of 
DDDs1 (CI2) 
Serious 
reports  
OR 
adjusted 
for individ. 
exposed1 
(CI2) 
OR 
adjusted 
for nr of 
DDDs1 (CI2) 
Total 419 343 564 
 
222 1.78 
(1.33-2.39) 
1.69 
(1.26-2.26) 
137 2.69 
(1.77-4.07) 
2.55 
(1.68-3.86) 
Women 248 051 341 
 
160 NA NA 109 NA NA 
Men 171 292 223 
 
62 NA NA 28 NA NA 
1 OR women vs men, 2 0.95 Confidence Interval  
 
Table 6. Reports and exposure data for diuretics and potassium-sparing agents (ATC code C03EA) 2005-2012. 
Modified from Paper III [101] 
 Individuals 
exposed 
Number of 
million 
DDDs 
Total 
reports 
OR 
adjusted 
for individ. 
exposed1 
(CI2) 
OR 
adjusted 
for nr of 
DDDs1 (CI2) 
Serious 
reports  
OR 
adjusted 
for individ. 
exposed1 
(CI2) 
OR 
adjusted 
for nr of 
DDDs1 (CI2) 
Total 244373 
 
307 
 
256 1.62 
(1.22-2.17) 
1.48 
(1.11-1.98) 
163 2.20 
(1.48-3.28) 
2.01 
(1.35-2.99) 
Women 163231 211 
 
196 NA NA 133 NA NA 
Men 81142  96 
 
60 NA NA 30 NA NA 
1 OR women vs men, 2 0.95 Confidence Interval  
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Table 8. Reports and exposure data for aldosterone antagonists (ATC code C03DA) 2005-2012. Modified from 
Paper III [101] 
 Individuals 
exposed 
Number of 
million 
DDDs 
Total 
reports 
OR 
adjusted 
for individ. 
exposed1 
(CI2) 
OR 
adjusted 
for nr of 
DDDs1 (CI2) 
Serious 
reports  
OR 
adjusted 
for individ. 
exposed1 
(CI2) 
OR 
adjusted 
for nr of 
DDDs1 (CI2) 
Total 258 422 
 
104 
 
246 0.75 
(0.59-0.97) 
0.60 
(0.46-0.77) 
178 0.78 
(0.58-1.05) 
0.62 
(0.46-0.83) 
Women 149 418  66 
 
125 NA NA 92 NA NA 
Men 109 004  38 
 
121 NA NA 86 NA NA 
1 OR women vs men, 2 0.95 Confidence Interval  
 
In several subgroups involving diuretics, hyponatremia was one of the most frequently 
reported ADEs. The age groups 50-74 and ≥75 years had the highest number of ADE-reports. 
There were more reports in women in the oldest age group (≥75 years), but after adjusting for 
prescription data, the ADE-report prevalence for each subgroup was in line with the main 
findings. 
 
5.4 PAPER IV 
232,624 patients (101,011 women and 131,613 men) were included in the cohort, with the 
women being older than men (72.2 vs 68.5 years), with an excess of patients in the age group 
≥80 years (study flowchart, Fig 1).  
Women had a lower incidence rate of severe bleeding compared to men (35 vs 38 events per 
1000 person-years) corresponding to a crude HR (95% CI) of 0.94 (0.90- 0.98). After 
adjustment, the HR was further reduced to 0.85 (0.81-0.89).  
Women had a lower adjusted risk of CNS and urogenital bleeding compared to men, but the 
adjusted GI bleeding risk was similar in both sexes (Table 3). In the group of other bleedings, 
anemia was more common in women while epistaxis was more frequent in men. 
In the stratified analysis, the lower severe bleeding risk in women was independent of 
indications and HAS-BLED score and women in the age groups 40-49 and 50-59 had a 
higher risk of severe bleeding than men. Stratifying on comorbidities did not change the 
general pattern with a lower risk of severe bleeding in women, except for renal failure, 
COPD, and prior bleeding. In patients with renal failure, effect modification was found with 
an excessive risk in women compared to men while no significant sex difference in the 
bleeding risk was found in patients with COPD or prior bleeding. 
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Fig 1. Study flow chart 
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Table 3. Incidence rate (IR) of severe bleeding (per 1000 person years) among women and men on warfarin 
stratified by bleeding site. Adjusted hazard ratios based on Cox regression. 
 
  Women   Men   Women vs. Men 
 
N IR (95% CI) N IR (95% CI) Adjusted HR 
(95% CI) 
Any severe bleeding* 3406 35.4 (34.2-36.6) 4759 37.8 (36.8-38.9) 0.84 (0.80-0.88) 
CNS bleeding 683 7.1 (6.6-7.7) 969 7.7 (7.2-8.2) 0.79 (0.71-0.87) 
GI bleeding 1098 11.4 (10.8-12.1) 1303 10.4 (9.8-10.9) 0.98 (0.90-1.06) 
Urogenital bleeding 364 3.8 (3.4-4.2) 966 7.7 (7.2-8.2) 0.41 (0.36-0.47) 
Other bleeding 1417 14.7 (14.0-15.5) 1731 13.8 (13.1-14.4) 1.03 (0.96-1.11) 
* As bleeding from multiple sites may occur, the numbers of site-specific bleeding events exceed the total number of severe bleeding events 
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6 DISCUSSION 
6.1 METHODOLOGICAL CONSIDERATIONS 
In the perfect world, the true prevalence and incidence of ADEs may be determined in a 
randomized, controlled interventional study, with the ability to assess the ADEs through 
direct patient contact. However, it is almost impossible to achieve a sufficiently large patient 
population, not to mention the high cost and the personal resources. In order to achieve 
sufficient statistical power analysis of sex and gender differences require even larger studies. 
Thus, healthcare registers with large coverage and the possibility of retrieving nationwide and 
structured data, can be used. Limitations of these registers and the methodological 
considerations are discussed below. 
 
6.1.1 Spontaneous reporting and pharmacovigilance databases 
Sex differences in spontaneous reports (study II and III) are presented as linkage between 
ADE-reports and drug utilization at the population level rather than the individual level [102]. 
Thus, an adjustment for potential confounding was not performed. Furthermore, since not all 
ADEs are reported the data do not represent the real incidence rate, but rather may be 
considered a proportion of the incidence. In contrast to the large international ADE database 
of the WHO, Vigibase [103] and other pharmacovigilance databases, the smaller SWEDIS 
database has a higher quality and reliability, i.e. all reports were provided by health care 
professionals and causality has been assessed which increases the reliability in comparison to 
other. The causality subclassification of ADEs into “serious” and “non-serious” in SWEDIS 
is of great advantage for the scientific evaluation. In general, women report more physical 
symptoms and use  medical services to a larger extent than men [104]. However, the 
propensity of reporting a serious ADE should not differ between women and men. 
Spontaneous reports of ADEs are only to be considered as signals requiring further 
assessment (e.g. temporal relationships, published case reports, biological, and clinical 
plausibility, clinical trials data, and epidemiological studies in large healthcare databases), 
and the ADE-reports are not sufficient to establish a causal relationship [105-107]. Thus, 
research on pharmacovigilance databases has its limitations and the true prevalence of ADEs 
may not be detected [105].  
 
6.1.2 Emergency care setting and chart reviews  
The selection of patients in the emergency care ward (study I) was based on randomization. 
However, we cannot entirely rule out the risk of selection bias. Clinical pharmacologists 
assessed all ADRs, if needed a specialized registered nurse working with ADR reporting at 
the MPA was consulted Established criteria were used when classifying the ADR-symptoms. 
Furthermore, the study population was not large enough to obtain significant differences 
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between women and men in the descriptive statistical analyses. In addition, we did not 
analyze if the correlation between the number of concomitant drugs and if the ADRs were 
due to comorbidities. Generalization of our results is difficult since the prevalence of ADRs 
strongly depends on setting and other circumstances. In studies using other methods than 
medical chart reviews, the prevalence of hospitalizations due to medication is lower [108]. 
 
6.1.3 Healthcare register studies 
Using Swedish administrative healthcare registers in epidemiological research such as the 
PDR and the NPR when evaluating effectiveness and safety of drug therapies provides 
several advantages. These registers consist of already structured data and cover large parts of 
the healthcare system over a long period. The PIN makes it possible to link data on exposure 
or treatment from other sources to outcomes in these healthcare data registers [88, 109]. The 
limitations of using healthcare register studies are discussed below. 
6.1.3.1 Selection bias 
The two studies on spontaneous reporting (study II and III) have the advantage of the use of 
nationwide patient identity drug databases, both regarding pharmacovigilance, and dispensed 
prescription data [110]. In study IV, the use of population-based healthcare registers with full 
coverage implies that there is no overall selection bias affecting the study population although 
there is still a risk of bias with a possible sex difference due to selective prescribing.  
6.1.3.2 Misclassification and confounding 
There are limitations to studies using diagnoses (ICD-10-codes) from healthcare registers 
because the diagnoses could be inaccurate and information might be missing. A systematic 
lack of information might lead to misclassification and residual confounding [109]. In study 
IV, sex and gender differences in receiving a certain diagnosis depend on the physician or 
patient attitudes and the healthcare consumption of patients which potentially could lead to 
differences between women and men in the number of patient diagnoses and comorbidities 
recorded in the registers (differential misclassification). 
A confounder is a factor associated with both the exposure and the outcome that does not lie 
on the causative pathway. A confounder may bias the observed effect of the exposure on the 
outcome. There are different ways to control for confounding in an observational study, such 
as stratification and adjusting for confounding variables using a multivariable regression 
analysis. There may also be exposure-associated unmeasured or poorly measured risk factors 
of the outcome, referred to as unobserved, unmeasured or misclassified confounders. This 
may lead to incomplete adjustment and residual confounding [111, 112].  
To control for confounding in study IV, the analyses were adjusted for age, indications, 
comorbidities, and co-medications, and stratified analyses were performed. After adjustment, 
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the sex difference remained, and was even more accentuated when compared with the crude 
estimate.  
6.1.3.3 Confounding by indication 
A major limitation of observational comparative effectiveness and safety studies is 
confounding by indication of therapy [113]. This is because those who are prescribed a 
certain drug are generally different from those who are not given this certain drug, according 
to the medical indication for which the drug was prescribed [114]. The drug prescribing 
physician is influenced by many different factors and certain types of patients will be 
prescribed certain types of drugs based on their indications and contraindications. The 
inability to compensate for differences in patient characteristics between treatment groups 
when comparing outcomes is called residual confounding.  
Both the choice of treatment and the outcomes might be affected by unmeasurable baseline 
factors, which could lead to confounding by indication. Additionally, different utilization or 
management of healthcare treatments in the observational study population, compared to a 
RCT, might also explain unexpected differences in outcomes between treatment groups 
[113]. Generally, patients in routine care are older with more co-morbidities and a higher 
discontinuation and lower adherence to treatment, compared to the trial patients.  
In study IV, we did not compare treated with untreated neither did we compare two different 
treatments but we compared two subpopulations e.g. women and men receiving the same 
treatment. Treatment choice could however be different between women and men and within 
the study design we could not consider if women and men were given treatment to the same 
extent. Despite adjustments for comorbidities some potential differences in frailty between 
men and women may not have been reflected in our confounding variables. 
6.1.3.4 Effect modification and interaction by sex 
Effect modification is the ability of a third factor (here, sex) to modify or interact with the 
“main effect” of the exposure (say, treatment) on outcome (usually, disease) [115]. As an 
example, from study IV, if the association between a certain variable (e.g. indication for 
warfarin, comorbidity, co-medication) and the outcome (bleeding event during warfarin 
treatment) were to be stronger for women compared to men, then it is said that sex “interacts” 
with that variable (e.g., renal failure) to cause bleeding events during warfarin treatment or 
that sex “modifies” the renal-failure-and-warfarin-induced-bleeding-event association (study 
IV; Table 4).  
6.1.3.5 Validity of diagnoses, treatments and outcomes 
The validity of hospital diagnoses in Sweden is well documented [85-89], while primary care 
diagnoses are less validated [116-118]. We did not have complete information on 
comorbidities because we lacked primary care diagnoses. The PDR lacks information on 
indications, and therefore we used diagnoses from the NPR that corresponded to the 
indications for warfarin treatment. 
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The prescription data only consists of dispensed prescriptions and therefore we lacked 
information on patients’ compliance to treatment, a limitation study II, III, and IV all have in 
common. Also, when assessing drug exposure from dispensed prescription data there is a risk 
of drug exposure misclassification, classifying a patient as exposed when truly the patient 
was unexposed [81]. Although, by using dispensed prescription data, there is no risk of recall 
bias [109].  
As primary outcome diagnoses for severe bleeding in study IV, we used the definitions (ICD-
10 codes) validated by Friberg et al. [119], identified in the NPR as main or secondary 
diagnosis. 99.4% of intracranial bleedings events and 82.6% of gastrointestinal bleeding 
events were identified correctly in the registries. The sensitivity was 85.5% and the 
specificity 95.9% for major bleeding events in this validation study [119]. 
6.1.3.6 Generalizability 
Warfarin treatment requires monitoring to maintain the International Normalized Ratio (INR) 
in plasma within the therapeutic range (2.0-3.0) [120], and a high time in therapeutic range 
(TTR) is associated with a lower risk of bleeding and thromboembolic events. There can be 
large differences in TTR between centers and countries. Among 44 countries, Sweden had 
the highest mean TTR in an efficacy and safety analysis of RE-LY trial data [121]. Therefore, 
the results found in study IV might not be reproducible in countries with warfarin treatment 
of a lower quality. 
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6.2 MAIN FINDINGS AND INTERPRETATION 
6.2.1 ADRs in emergency medicine 
The emergency ward is an ideal place to detect and assess the prevalence of ADRs with its 
high throughput of patients. In almost 20 percent of the study patients, ADRs had caused or 
contributed to hospital admission, in line with previous Swedish reports from a geriatric 
clinic and an internal medicine ward [44, 122]. In several meta-analyses, including not only 
emergency care data [48, 123-127], a lower incidence of ADR-related hospital admission was 
presented. In some of these studies, not only the patient population, but also the assessment of 
ADRs differed from our study. Patients admitted to hospital due to ADRs in our study were 
older and had a higher number of concomitant drugs than those admitted for other reasons, 
which is in line with other studies [46, 128]. The oldest patients (85+) in our study had the 
largest difference between women and men in ADR-admissions, which is also in line with 
other reports [34-38].  
The most common drugs causing or contributing to hospital admission in our study were 
those with cardiovascular indications, followed by antineoplastic agents. The pattern of 
causative drugs may differ depending on the constitution of patient care at the studied 
hospital. The results in our study can in part be explained by the relatively high number of 
patients treated at the thoracic and oncology clinics.  
Drug-safety issues differ depending on geography and the level of healthcare, and ways to 
address local safety problems have been presented in the literature [129]. In our study when 
assessing preventability, we focused on the ADRs with the largest impact on patient health 
and compared to other studies [130-132], and we found less preventable ADRs. Most 
preventable ADRs were caused by antihypertensives and antithrombotics and could have 
been avoided by better monitoring, e.g. BP, heart rate, therapeutic drug monitoring 
(TDM)/functional coagulation tests, of cardiovascular drugs given in combination and 
avoiding the combination of SSRIs and aspirin in patients with a high bleeding risk.  
We found a substantial under-reporting of ADRs to national authority. The reasons for the 
under-reporting could be lack of implemented routines, lack of time while on duty and, 
unawareness. The reporting rate could perhaps be improved by making the healthcare 
professionals more aware of ADRs through built in routines and continuous education. 
Additionally, if there were to be financial incentives for reporting side effects, e.g. if the 
activity would be subsidized, together with facilitating the reporting process, would also 
possibly improve the rate of reporting.  
The chart reviews in this study provided valuable ADR-data, but unfortunately the study 
population was not big enough to be able to sufficiently assess sex differences. One way to 
get a larger study population would have been to involve several hospitals in the Stockholm 
region, but that would require adequate resources and infrastructure. 
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6.2.2 Spontaneous reported ADEs from cardiovascular medicines  
When studying spontaneous reporting, one should always know the data do not represent the 
real incidence rate but merely a proxy of it. Still data on sex differences within spontaneous 
reporting could give valuable information about differences in safety of drug treatment. In 
both studies on reported ADEs (study II and III), we adjusted for the number of individuals 
exposed, the number of dispensed prescriptions, and the number of DDDs. We believe the 
use of individualized data to be more accurate, reflecting the number of exposed individuals 
which is comparable to the safety population in a RCT. In pharmacoepidemiological studies 
it is common to use the number of dispensed prescriptions as a measure of exposed patients 
[133], due to the lack of nationwide patient identity drug databases which are only available 
in a few other countries [110]. The nationwide coverage of the database and the use of 
individualized data are two advantages compared to other pharmacovigilance studies found in 
the literature. Furthermore, we believe that the validation of the results with the secondary 
analyses of serious reports, is an advantage when analyzing differences between women and 
men. The number of total reports is significantly lower in SWEDIS compared to the 
international pharmacovigilance database, Vigibase, which is of course a noticeable 
limitation. 
6.2.2.1 Sex differences in reported bleeding events from antithrombotic treatment 
The prevalence of reported bleeding events in women compared to men, adjusted for the 
number of exposed patients, differed for the three studied substances; clopidogrel, low-dose 
aspirin and warfarin. For clopidogrel, when adjusting for patients exposed, women had a 
higher prevalence of reported bleeding events. Therefore, similar sex patterns for the even 
more potent antiplatelet drugs, like prasugrel and ticagrelor, could be interesting to follow. In 
contrast, for low-dose aspirin the reported bleeding risk was higher in men. The proportion of 
patients receiving 160 or 320 mg was higher in men as compared to women. Additionally, 
aspirin resistance, i.e., the inability of aspirin to protect patients from thrombotic 
complications, has been found to be more common in women in some studies [134-136], but 
not in others [137, 138], which also could play a role for the higher reported bleeding risk in 
men. Monitoring and individualized dosing could be reasonable explanations to the results 
for warfarin with no sex difference in reported bleeding events. In our attempt to estimate 
concomitant use of other antithrombotic treatment we found that co-prescription of more than 
one antithrombotic treatment was more common in men. An increased risk of bleeding is 
associated with dual antiplatelet therapy (DAT) [139], and for patients with oral 
anticoagulants the risk of developing bleeding complications is further enhanced [140-142]. 
The higher percentage of reports on CNS and GI bleeding in men for all three substances 
found in our study could possibly also reflect more intense antithrombotic combination 
treatments [143]. 
6.2.2.2 Sex differences in ADE-reports from common antihypertensives 
Our findings with higher prevalence of reported ADEs for women in six of the ten subgroups 
of antihypertensives are in line with the greater risk of ADR-related admissions to hospital 
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found in women [37, 48, 144]. At the same time, there are data on sex and gender differences 
in the spontaneous reporting of ADEs pointing to women generally reporting more symptoms 
[75, 76]. Our findings are plausible from a mechanistic standpoint, with women frequently at 
higher risk for dose-dependent ADRs due to differences between women and men in 
pharmacokinetics and exposure [18]. For the antihypertensives with more reports in women, 
a higher dose exposure was found, which is also seen in the literature with a relatively higher 
exposure in women to a given dose [19]. The different effect of sex hormones on the RAAS 
could also be part of an explanation in the case of ACE-Is and ARBs, with estrogens 
downregulating and androgens upregulating the RAAS [27]. Although, it has not yet been 
established if the hormonal influences on the RAAS have an impact on efficacy and safety of 
the RAAS-agents [17].  
The higher prevalence of ADE-reports found in women for thiazides and diuretics with 
potassium sparing agents could partially be explained by women being more susceptible to 
drug-induced hyponatremia and other electrolyte disturbances caused by drug treatment 
[145]. Female sex is one of the risk factors of thiazide-induced hyponatremia [146], and is 
found to be four times more common in women [147]. In our study, the only group of 
antihypertensives with a higher prevalence of ADE-reports in men was aldosterone 
antagonists, possibly due to the higher prevalence of co-prescription of ACE-Is or ARBs in 
men, with the risk of hyperkalemia. There are gender differences in prescription patterns and 
a study with Swedish primary care data found that men were more often treated with ACE-Is 
and women with diuretics, but no difference between women and men was found for the 
average number of antihypertensive drug classes. Furthermore, men interrupted their 
treatment to a higher extent and BP was less well controlled in women [148]. A gender 
difference in persistence to BP treatment was found in another Swedish primary care study 
[149], which of course could be a confounder to our finding with a higher prevalence of 
ADE-reports in women. 
 
6.2.3 Sex differences in bleeding events during warfarin treatment 
In study IV, we found that the risk of severe bleeding was lower in women, with the lower 
risk even more pronounced after adjustments, and with the CNS bleeding risk following the 
same pattern. A similar finding, with a lower bleeding risk in women, has been found in the 
literature [62]. In our study, sex differences in age, comorbidities and co-medication could 
not explain a lower total incidence of severe bleeding in women. In certain subgroups, e.g. in 
patients with renal failure and in the age groups of 40-49 and 50-59, the overall pattern was 
reversed with a higher bleeding risk in women. We did find sex differences in comorbidities 
and co-medication, with hypertension and ischemic stroke or TIA more frequent among 
women while MI and ischemic heart disease were more frequent in men, and more men were 
treated with other antiplatelet agents compared to women, consistent with findings in the 
literature [67, 150-154]. Furthermore, the combination of warfarin with other antiplatelet 
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agents was associated with a higher severe bleeding risk in our study, was also in line with 
other findings [155].  
When interpreting our results with the lower bleeding risk in women, the differences in stroke 
epidemiology between women and men must be considered, which affect the risk benefit 
balance for stroke prevention in women with AF on warfarin. Studies have found a higher 
risk of stroke in women [59, 156], and with a suggestion of a possible higher net clinical 
benefit of VKA treatment in women [61]. The results in our study could partially be 
explained by differences in prescription patterns with the physicians not prescribing 
anticoagulation treatment to women with a high bleeding risk to the same extent as in high 
risk men, especially in the elderly. A more direct evaluation of benefit-risk could be obtained 
by studying the possible sex differences in the incidence of stroke and recurrence of VTE 
during warfarin treatment, either as separate or as co-primary outcomes. 
Additionally, we lacked data on BP control in the NPR and the lower severe bleeding risk in 
women could potentially partially be explained by sex/gender differences in hypertension 
control. We also lacked data on INR (international normalized ratio) and TTR, which also 
could be part of an explanation of the results. Thus, including information about sex and/or 
gender differences in factors influencing treatment choices and intensity, BP and INR, in 
additional studies could possibly clarify our findings. 
Although NOACs are currently stepwise replacing VKA as first-line therapy in e.g. stroke 
prevention in atrial fibrillation (SPAF) our results are of interest. VKAs are still prescribed in 
many countries/regions, indications, and situations and therefore possible sex and gender 
differences, as highlighted here, merit further studies. 
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7 CONCLUSIONS 
In this thesis, I have investigated sex differences in ADEs from cardiovascular medicines in 
routine care. The overall conclusion is that there are sex differences in reported ADEs from 
clopidogrel, low-dose aspirin and common antihypertensive treatment and bleeding events 
from warfarin. From the analyses we concluded that: 
 
- ADRs were common in Emergency medicine in tertiary care in Sweden, and the 
under-reporting of ADRs to national authority was substantial. The ADRs were 
significantly associated with age and number of drugs. The ADRs were most 
frequently caused by cardiovascular medicines. 
 
- For clopidogrel, there was a signal towards a higher prevalence of reported bleeding 
events in women, with standard dosing as a possible explanation. For low-dose 
aspirin, a lower prevalence of bleeding event reports was found in women, possibly 
explained by higher dosing in men.  
 
 
- A higher prevalence of ADE-reports was found in women using ACE-Is, ACE-I-
combinations, ARB-combinations, thiazides, diuretics and potassium-sparing agents 
and DHPs, with a potential linkage to dose exposure. The only group with a higher 
prevalence of reports in men was aldosterone antagonists, with a similar dose 
exposure in women and men.  
 
- In the population-based cohort study with patients treated with warfarin, we found a 
lower incidence of severe bleeding in women, corresponding to a lower overall 
bleeding risk even after adjusting for age, comorbidities, and co-medications. We also 
found a lower risk of CNS and urogenital bleeding in women. However, women had a 
higher risk of severe bleeding compared to men among the middle-aged and in 
patients with renal failure. 
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8 FUTURE PERSPECTIVES 
As a take-home-message from this thesis, there is a need of more and more reliable data on 
sex and gender differences concerning the safety aspect of cardiovascular treatment. To be 
able to answer the question of who has a higher risk of experiencing a side effect, data on sex 
differences in ADEs is one of the prerequisites for individualized drug treatment. Already in 
the development of new drugs, data on sex differences in ADEs should be presented in the 
pivotal RCTs preceding registration of the drug on the market. Sex and gender analyses 
should also be included in the post-marketing surveillance of ADEs. 
To facilitate researching and obtaining sex-specific data, the accessibility and usage of the 
electronic patient record and pharmacovigilance databases should be improved. Having 
access to nationwide patient data through a common and user-friendly electronic patient 
record with the possibility of directly e-reporting should improve both the quantity and the 
quality of clinically related drug safety data. This of course comes with several ethical and 
legal aspects to consider, but the potential of improved drug safety should be considered.  
The pharmacovigilance databases should be designed and adapted to research containing 
structured and easily accessible data. The data in SWEDIS consisted of solid but less 
accessible safety data, and with the disadvantage of fewer reports compared to the 
international database Vigibase. The new legislation from 2012 broadening the inclusion of 
reports into the national pharmacovigilance database BiSi changed the quality and 
accessibility of data for the clinical researcher. However, the ADE-reports in BiSi are 
included in the European pharmacovigilance database, EudraVigilance, and adapting this 
database to research would most certainly widen the horizon for drug safety research. 
Therefore, by using this database in future pharmacovigilance studies, a larger study 
population would bring more and better information on the sex differences of reported ADEs 
from cardiovascular medicines in routine care.  
Considering the results here presented, it would be of special interest to study sex and gender 
differences concerning ADEs from the more recently introduced antiplatelet drugs prasugrel 
and ticagrelor. Furthermore, it would be highly important to study NOACs, given that these 
are prescribed in standard doses and usually still without monitoring. 
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9 SVENSK SAMMANFATTNING 
Läkemedelsbehandling av hjärtkärlsjukdom består till stor del av förebyggande behandling, 
och framförallt när det gäller preventiva läkemedelsbehandlingar så är risken stor att 
patienten inte fortsätter sin behandling vid uppkomst av läkemedelsbiverkningar, vilket i sin 
tur kan leda till en ökad risk för stort lidande, funktionella handikapp och för tidig död. Ökad 
kunskap om eventuella skillnader i läkemedelsbiverkningar hos kvinnor och män kan i sin tur 
leda till att läkemedelsbehandlingen bättre anpassas efter individen. Detta kan öka chanserna 
för att patienten fortsätter med sin preventiva behandling. Det övergripande syftet med 
avhandlingen är att få ökad kunskap om och förståelse för könsskillnader i 
läkemedelsbehandling av hjärtkärlsjukdom, med särskilt fokus på blödningar som orsakats av 
läkemedel för att förebygga blodproppar, specifikt warfarin.  
Den första delstudien i avhandlingen beskriver förekomsten av och möjligheten att förebygga 
läkemedelsbiverkningar samt och spontan biverkningsrapportering på en akutvårdsavdelning 
på Karolinska Universitetssjukhuset Solna. Studien visar att fyrtio procent av patienterna 
hade minst en möjlig läkemedelsbiverkan, och närmare en femtedel av patienterna hade 
biverkningar som orsakat eller bidragit till sjukhusinläggning, varav cirka en fjärdedel 
bedömdes som förebyggbara. De vanligaste förekommande biverkningarna var orsakade av 
läkemedelsbehandlingar mot hjärtkärlsjukdom, och spontan biverkningsrapportering förekom 
i mycket liten utsträckning. 
Den andra delstudien beskriver könsskillnader i rapporterade blödningar orsakade av tre olika 
läkemedel mot blodpropp: klopidogrel, lågdos acetylsalicylsyra (ASA) samt warfarin. 
Studien visar att fler män behandlades med klopidogrel men att rapporterade blödningar 
orsakade av klopidogrel var vanligare hos kvinnor. Rapporterade blödningar orsakade av 
lågdos-ASA var däremot vanligare hos män samtidigt som det inte fanns någon könsskillnad 
i blödningsrapporter orsakade av warfarin.  
Den tredje delstudien undersökte könsskillnader i samtliga biverkningsrapporter för vanligt 
förekommande läkemedel mot högt blodtryck. I sex av tio av de läkemedelsgrupper som 
undersöktes så fanns det totalt fler biverkningsrapporter för kvinnor, med tecken till att dosen 
i dessa fall kunde haft betydelse.  
Den fjärde delstudien undersökte könsskillnader i allvarliga blödningar orsakade av warfarin 
och den visade att dessa förekom i mindre utsträckning hos kvinnor, vilket även gällde risken 
för bland annat hjärnblödningar, specifikt. Risken för allvarliga blödningar var lägre hos 
kvinnor även efter det att man tagit hänsyn till ålder, andra sjukdomstillstånd och övrig 
läkemedelsbehandling. 
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